| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Female | 395 | 2025 | 9103 | 10.920 |
Why?
|
| Urban Population | 57 | 2025 | 257 | 10.710 |
Why?
|
| Humans | 469 | 2025 | 14537 | 10.550 |
Why?
|
| Obesity | 64 | 2025 | 367 | 10.510 |
Why?
|
| South Africa | 310 | 2025 | 7596 | 10.220 |
Why?
|
| Hypertension | 36 | 2025 | 419 | 9.310 |
Why?
|
| Body Mass Index | 72 | 2025 | 321 | 9.240 |
Why?
|
| Diabetes, Gestational | 22 | 2024 | 38 | 8.060 |
Why?
|
| Adolescent | 163 | 2025 | 2985 | 7.790 |
Why?
|
| Adult | 218 | 2025 | 5913 | 7.350 |
Why?
|
| Male | 252 | 2025 | 6754 | 7.230 |
Why?
|
| Body Composition | 44 | 2024 | 153 | 7.100 |
Why?
|
| Adiposity | 25 | 2024 | 96 | 6.640 |
Why?
|
| Diet | 29 | 2023 | 109 | 6.370 |
Why?
|
| Young Adult | 120 | 2025 | 2498 | 6.230 |
Why?
|
| Exercise | 34 | 2023 | 205 | 6.000 |
Why?
|
| Child | 141 | 2024 | 2242 | 5.860 |
Why?
|
| Pregnancy | 107 | 2024 | 1862 | 5.780 |
Why?
|
| Diabetes Mellitus, Type 2 | 26 | 2025 | 139 | 5.680 |
Why?
|
| Birth Weight | 29 | 2023 | 80 | 4.810 |
Why?
|
| Overweight | 20 | 2023 | 87 | 4.700 |
Why?
|
| Blood Pressure | 26 | 2023 | 317 | 4.700 |
Why?
|
| Health Knowledge, Attitudes, Practice | 19 | 2025 | 262 | 4.440 |
Why?
|
| Cross-Sectional Studies | 79 | 2025 | 1422 | 4.420 |
Why?
|
| Weight Gain | 22 | 2024 | 77 | 4.410 |
Why?
|
| Child, Preschool | 86 | 2024 | 1748 | 4.210 |
Why?
|
| Pediatric Obesity | 14 | 2024 | 41 | 4.200 |
Why?
|
| Feeding Behavior | 15 | 2021 | 60 | 4.130 |
Why?
|
| Rural Population | 30 | 2025 | 654 | 4.120 |
Why?
|
| Growth Disorders | 18 | 2023 | 56 | 4.120 |
Why?
|
| Child Development | 25 | 2024 | 93 | 4.100 |
Why?
|
| Qualitative Research | 29 | 2025 | 321 | 4.100 |
Why?
|
| Risk Factors | 77 | 2025 | 1475 | 4.060 |
Why?
|
| Prevalence | 66 | 2025 | 1192 | 4.020 |
Why?
|
| Cohort Studies | 77 | 2024 | 967 | 3.870 |
Why?
|
| Socioeconomic Factors | 45 | 2025 | 411 | 3.710 |
Why?
|
| Breast Neoplasms | 14 | 2024 | 131 | 3.650 |
Why?
|
| Mothers | 28 | 2023 | 195 | 3.610 |
Why?
|
| Middle Aged | 108 | 2025 | 3601 | 3.590 |
Why?
|
| Nutritional Status | 18 | 2023 | 76 | 3.530 |
Why?
|
| Infant, Newborn | 73 | 2024 | 1479 | 3.500 |
Why?
|
| Infant | 74 | 2024 | 2244 | 3.450 |
Why?
|
| Body Height | 24 | 2024 | 52 | 3.360 |
Why?
|
| Social Class | 20 | 2025 | 73 | 3.350 |
Why?
|
| Health Services Accessibility | 14 | 2024 | 280 | 3.340 |
Why?
|
| Hyperglycemia | 8 | 2022 | 15 | 3.300 |
Why?
|
| Mental Health | 8 | 2024 | 91 | 3.270 |
Why?
|
| Body Weight | 19 | 2021 | 111 | 3.250 |
Why?
|
| Health Behavior | 13 | 2021 | 79 | 3.140 |
Why?
|
| Cardiovascular Diseases | 12 | 2022 | 237 | 2.880 |
Why?
|
| HIV Infections | 51 | 2025 | 5097 | 2.800 |
Why?
|
| Life Style | 19 | 2025 | 86 | 2.780 |
Why?
|
| Lead | 7 | 2022 | 33 | 2.710 |
Why?
|
| Longitudinal Studies | 50 | 2025 | 435 | 2.690 |
Why?
|
| Body Image | 6 | 2019 | 17 | 2.540 |
Why?
|
| Anthropometry | 29 | 2024 | 102 | 2.530 |
Why?
|
| Adolescent Behavior | 12 | 2021 | 60 | 2.440 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 146 | 2.440 |
Why?
|
| Blood Glucose | 13 | 2024 | 107 | 2.430 |
Why?
|
| Surveys and Questionnaires | 35 | 2025 | 563 | 2.430 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 5 | 2020 | 13 | 2.410 |
Why?
|
| Fetal Development | 10 | 2023 | 19 | 2.390 |
Why?
|
| Noncommunicable Diseases | 9 | 2023 | 77 | 2.340 |
Why?
|
| Focus Groups | 12 | 2025 | 196 | 2.310 |
Why?
|
| Breast Feeding | 9 | 2020 | 120 | 2.210 |
Why?
|
| Metabolic Syndrome | 10 | 2022 | 64 | 2.120 |
Why?
|
| Poverty | 13 | 2022 | 152 | 2.110 |
Why?
|
| Health Promotion | 9 | 2024 | 109 | 2.090 |
Why?
|
| Sex Factors | 27 | 2023 | 227 | 2.080 |
Why?
|
| Developing Countries | 23 | 2024 | 400 | 2.070 |
Why?
|
| Public Health | 7 | 2024 | 124 | 2.040 |
Why?
|
| Adolescent Development | 7 | 2021 | 13 | 1.900 |
Why?
|
| Food Supply | 6 | 2024 | 29 | 1.890 |
Why?
|
| Multimorbidity | 6 | 2023 | 42 | 1.880 |
Why?
|
| Malnutrition | 10 | 2021 | 56 | 1.880 |
Why?
|
| Metabolic Diseases | 7 | 2019 | 30 | 1.830 |
Why?
|
| Social Support | 14 | 2025 | 77 | 1.820 |
Why?
|
| Aged | 42 | 2025 | 1740 | 1.780 |
Why?
|
| Community Health Workers | 5 | 2024 | 66 | 1.740 |
Why?
|
| Bone Density | 25 | 2023 | 107 | 1.740 |
Why?
|
| Child Nutritional Physiological Phenomena | 8 | 2023 | 19 | 1.660 |
Why?
|
| Pregnancy Complications | 10 | 2022 | 55 | 1.660 |
Why?
|
| Prospective Studies | 43 | 2024 | 1160 | 1.630 |
Why?
|
| Growth | 6 | 2020 | 14 | 1.620 |
Why?
|
| Family Characteristics | 10 | 2022 | 135 | 1.550 |
Why?
|
| Adipose Tissue | 15 | 2024 | 52 | 1.530 |
Why?
|
| Environmental Exposure | 5 | 2018 | 45 | 1.520 |
Why?
|
| Neoplasms | 5 | 2023 | 147 | 1.500 |
Why?
|
| Interviews as Topic | 16 | 2024 | 203 | 1.440 |
Why?
|
| Eating | 3 | 2017 | 16 | 1.440 |
Why?
|
| Puberty | 12 | 2021 | 22 | 1.420 |
Why?
|
| Caregivers | 7 | 2020 | 76 | 1.420 |
Why?
|
| Mastectomy | 3 | 2020 | 10 | 1.420 |
Why?
|
| Depression | 9 | 2024 | 121 | 1.380 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2023 | 21 | 1.380 |
Why?
|
| Preconception Care | 5 | 2018 | 12 | 1.380 |
Why?
|
| Gestational Age | 13 | 2022 | 80 | 1.340 |
Why?
|
| Prenatal Diagnosis | 3 | 2022 | 22 | 1.340 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2024 | 33 | 1.330 |
Why?
|
| Aggression | 3 | 2022 | 13 | 1.330 |
Why?
|
| Pregnancy Complications, Infectious | 12 | 2021 | 529 | 1.310 |
Why?
|
| Urban Health | 13 | 2021 | 78 | 1.310 |
Why?
|
| Insulin Resistance | 6 | 2022 | 79 | 1.300 |
Why?
|
| Research Design | 12 | 2022 | 124 | 1.280 |
Why?
|
| Aging | 6 | 2021 | 109 | 1.270 |
Why?
|
| Anxiety Disorders | 3 | 2024 | 15 | 1.250 |
Why?
|
| Educational Status | 12 | 2022 | 68 | 1.250 |
Why?
|
| Logistic Models | 15 | 2021 | 254 | 1.250 |
Why?
|
| Prenatal Care | 9 | 2024 | 147 | 1.240 |
Why?
|
| Residence Characteristics | 5 | 2019 | 57 | 1.220 |
Why?
|
| Africa | 22 | 2025 | 376 | 1.220 |
Why?
|
| Patient Acceptance of Health Care | 9 | 2024 | 256 | 1.210 |
Why?
|
| Glucose Tolerance Test | 11 | 2021 | 33 | 1.200 |
Why?
|
| Health Status | 5 | 2022 | 111 | 1.190 |
Why?
|
| Violence | 4 | 2018 | 68 | 1.170 |
Why?
|
| Smoking | 7 | 2023 | 100 | 1.170 |
Why?
|
| Africa South of the Sahara | 20 | 2025 | 353 | 1.170 |
Why?
|
| Stress, Psychological | 7 | 2022 | 28 | 1.160 |
Why?
|
| Adolescent Health Services | 4 | 2024 | 17 | 1.160 |
Why?
|
| Rural Health | 5 | 2017 | 118 | 1.140 |
Why?
|
| Self Report | 5 | 2025 | 114 | 1.130 |
Why?
|
| Absorptiometry, Photon | 26 | 2022 | 85 | 1.120 |
Why?
|
| Sanitation | 5 | 2020 | 17 | 1.110 |
Why?
|
| Obesity, Abdominal | 4 | 2018 | 19 | 1.050 |
Why?
|
| Weight Loss | 2 | 2020 | 12 | 1.050 |
Why?
|
| Menarche | 6 | 2023 | 13 | 1.040 |
Why?
|
| Bone Development | 11 | 2017 | 19 | 1.030 |
Why?
|
| Waist Circumference | 9 | 2025 | 60 | 1.020 |
Why?
|
| Ultrasonography, Prenatal | 9 | 2023 | 24 | 1.000 |
Why?
|
| Premature Birth | 8 | 2021 | 80 | 1.000 |
Why?
|
| Blood Pressure Determination | 3 | 2022 | 27 | 1.000 |
Why?
|
| Chronic Disease | 6 | 2023 | 107 | 1.000 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2024 | 19 | 1.000 |
Why?
|
| Follow-Up Studies | 19 | 2023 | 370 | 0.990 |
Why?
|
| Attitude of Health Personnel | 3 | 2024 | 106 | 0.990 |
Why?
|
| Pregnancy Outcome | 8 | 2021 | 117 | 0.970 |
Why?
|
| Genome-Wide Association Study | 7 | 2024 | 106 | 0.970 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 171 | 0.950 |
Why?
|
| Pandemics | 7 | 2025 | 296 | 0.950 |
Why?
|
| Life Change Events | 2 | 2023 | 9 | 0.940 |
Why?
|
| Motor Activity | 12 | 2021 | 46 | 0.910 |
Why?
|
| Bone and Bones | 8 | 2020 | 38 | 0.890 |
Why?
|
| Self Concept | 2 | 2016 | 13 | 0.890 |
Why?
|
| Personal Autonomy | 1 | 2025 | 6 | 0.880 |
Why?
|
| Psychometrics | 2 | 2024 | 22 | 0.880 |
Why?
|
| Health Literacy | 1 | 2024 | 4 | 0.870 |
Why?
|
| Patient Health Questionnaire | 1 | 2024 | 3 | 0.860 |
Why?
|
| Insulin | 4 | 2022 | 73 | 0.860 |
Why?
|
| Child Health | 3 | 2023 | 77 | 0.850 |
Why?
|
| Community Health Services | 5 | 2016 | 58 | 0.850 |
Why?
|
| Motivation | 1 | 2025 | 59 | 0.850 |
Why?
|
| Thinness | 6 | 2022 | 18 | 0.850 |
Why?
|
| Abortion, Induced | 1 | 2024 | 16 | 0.840 |
Why?
|
| Feasibility Studies | 1 | 2024 | 101 | 0.830 |
Why?
|
| Parturition | 3 | 2023 | 31 | 0.830 |
Why?
|
| Hemoglobins | 2 | 2023 | 40 | 0.800 |
Why?
|
| Alcohol Drinking | 6 | 2023 | 55 | 0.790 |
Why?
|
| Self Efficacy | 1 | 2023 | 11 | 0.770 |
Why?
|
| Vitamin D | 7 | 2021 | 41 | 0.770 |
Why?
|
| Iron | 3 | 2020 | 32 | 0.770 |
Why?
|
| Age Factors | 18 | 2019 | 370 | 0.770 |
Why?
|
| Checklist | 1 | 2023 | 5 | 0.770 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 96 | 0.770 |
Why?
|
| Intergenerational Relations | 2 | 2020 | 3 | 0.760 |
Why?
|
| Anemia | 1 | 2023 | 41 | 0.760 |
Why?
|
| Social Environment | 3 | 2019 | 11 | 0.760 |
Why?
|
| Tobacco Use | 2 | 2022 | 12 | 0.760 |
Why?
|
| Continuity of Patient Care | 2 | 2024 | 33 | 0.750 |
Why?
|
| Mother-Child Relations | 2 | 2020 | 20 | 0.750 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2021 | 472 | 0.750 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2010 | 16 | 0.740 |
Why?
|
| Income | 15 | 2022 | 85 | 0.740 |
Why?
|
| Healthy Aging | 1 | 2022 | 6 | 0.740 |
Why?
|
| Anti-Retroviral Agents | 4 | 2019 | 551 | 0.730 |
Why?
|
| HIV | 6 | 2023 | 380 | 0.720 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 217 | 0.710 |
Why?
|
| Comorbidity | 8 | 2020 | 188 | 0.710 |
Why?
|
| Tobacco | 1 | 2022 | 14 | 0.710 |
Why?
|
| Diarrhea | 2 | 2019 | 76 | 0.710 |
Why?
|
| Environmental Pollutants | 3 | 2018 | 16 | 0.700 |
Why?
|
| Hepatitis C, Chronic | 7 | 2017 | 26 | 0.700 |
Why?
|
| Sexual Behavior | 4 | 2021 | 320 | 0.700 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 39 | 0.690 |
Why?
|
| Parity | 1 | 2021 | 19 | 0.680 |
Why?
|
| Health Services Research | 4 | 2017 | 58 | 0.680 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 30 | 0.680 |
Why?
|
| Mammography | 1 | 2020 | 3 | 0.650 |
Why?
|
| Energy Metabolism | 2 | 2017 | 13 | 0.650 |
Why?
|
| Sexism | 1 | 2020 | 6 | 0.650 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 14 | 0.650 |
Why?
|
| Adolescent Health | 2 | 2021 | 15 | 0.650 |
Why?
|
| Hepatitis C | 5 | 2017 | 37 | 0.650 |
Why?
|
| Anxiety | 6 | 2024 | 40 | 0.650 |
Why?
|
| Biological Evolution | 3 | 2017 | 9 | 0.640 |
Why?
|
| Women's Health | 2 | 2024 | 41 | 0.640 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 10 | 0.640 |
Why?
|
| Schools | 7 | 2023 | 73 | 0.640 |
Why?
|
| Health Policy | 3 | 2021 | 140 | 0.630 |
Why?
|
| Sexual Health | 1 | 2020 | 14 | 0.630 |
Why?
|
| Nutrition Policy | 6 | 2021 | 19 | 0.630 |
Why?
|
| Cancer Survivors | 1 | 2020 | 3 | 0.620 |
Why?
|
| Altitude | 1 | 2020 | 9 | 0.620 |
Why?
|
| Allostasis | 1 | 2019 | 1 | 0.620 |
Why?
|
| Dietary Sugars | 1 | 2019 | 7 | 0.620 |
Why?
|
| Personal Satisfaction | 3 | 2016 | 16 | 0.610 |
Why?
|
| Pregnancy in Diabetics | 1 | 2019 | 2 | 0.610 |
Why?
|
| Attitude to Health | 2 | 2019 | 56 | 0.610 |
Why?
|
| Infant Nutritional Physiological Phenomena | 4 | 2017 | 17 | 0.600 |
Why?
|
| Mental Disorders | 2 | 2024 | 44 | 0.600 |
Why?
|
| Hexokinase | 1 | 2019 | 1 | 0.600 |
Why?
|
| Glucose Oxidase | 1 | 2019 | 3 | 0.600 |
Why?
|
| Models, Biological | 6 | 2018 | 77 | 0.590 |
Why?
|
| Energy Intake | 7 | 2020 | 24 | 0.590 |
Why?
|
| Infant Formula | 2 | 2018 | 5 | 0.590 |
Why?
|
| Global Health | 6 | 2024 | 193 | 0.590 |
Why?
|
| Models, Theoretical | 3 | 2019 | 80 | 0.590 |
Why?
|
| Human Development | 2 | 2016 | 3 | 0.580 |
Why?
|
| Hemochromatosis | 2 | 2010 | 5 | 0.580 |
Why?
|
| Cost of Illness | 4 | 2024 | 167 | 0.580 |
Why?
|
| Dyslipidemias | 4 | 2025 | 57 | 0.570 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2024 | 198 | 0.570 |
Why?
|
| Sleep | 5 | 2022 | 36 | 0.570 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 26 | 0.570 |
Why?
|
| Membrane Proteins | 2 | 2010 | 36 | 0.570 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2015 | 5 | 0.570 |
Why?
|
| Sex Characteristics | 10 | 2018 | 43 | 0.570 |
Why?
|
| Menstruation | 1 | 2018 | 10 | 0.570 |
Why?
|
| Taxes | 1 | 2019 | 73 | 0.570 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2025 | 21 | 0.560 |
Why?
|
| Women's Health Services | 1 | 2018 | 12 | 0.560 |
Why?
|
| Delivery of Health Care | 5 | 2021 | 239 | 0.550 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 31 | 0.550 |
Why?
|
| Sexual Maturation | 1 | 2018 | 2 | 0.550 |
Why?
|
| Time Factors | 12 | 2022 | 507 | 0.550 |
Why?
|
| Leg | 1 | 2018 | 21 | 0.550 |
Why?
|
| Cities | 3 | 2016 | 37 | 0.540 |
Why?
|
| Health Status Disparities | 2 | 2019 | 35 | 0.540 |
Why?
|
| Nutrition Assessment | 6 | 2018 | 12 | 0.530 |
Why?
|
| Retrospective Studies | 11 | 2022 | 799 | 0.530 |
Why?
|
| Parents | 4 | 2020 | 32 | 0.530 |
Why?
|
| Diet, Western | 1 | 2017 | 1 | 0.530 |
Why?
|
| Micronutrients | 3 | 2021 | 11 | 0.520 |
Why?
|
| Models, Statistical | 1 | 2017 | 55 | 0.520 |
Why?
|
| Lead Poisoning | 1 | 2017 | 9 | 0.520 |
Why?
|
| Depression, Postpartum | 3 | 2020 | 22 | 0.520 |
Why?
|
| Health Surveys | 8 | 2019 | 59 | 0.510 |
Why?
|
| Biomarkers | 7 | 2024 | 327 | 0.510 |
Why?
|
| Preventive Medicine | 1 | 2017 | 2 | 0.510 |
Why?
|
| Monitoring, Physiologic | 2 | 2016 | 25 | 0.500 |
Why?
|
| Social Stigma | 5 | 2024 | 80 | 0.500 |
Why?
|
| Nuclear Family | 1 | 2016 | 2 | 0.490 |
Why?
|
| Health Priorities | 2 | 2023 | 62 | 0.490 |
Why?
|
| Fractures, Bone | 6 | 2018 | 21 | 0.490 |
Why?
|
| Help-Seeking Behavior | 1 | 2016 | 2 | 0.490 |
Why?
|
| Antiviral Agents | 7 | 2017 | 111 | 0.480 |
Why?
|
| Prediabetic State | 1 | 2016 | 3 | 0.480 |
Why?
|
| Attitude | 1 | 2016 | 12 | 0.480 |
Why?
|
| Mobile Applications | 1 | 2016 | 12 | 0.480 |
Why?
|
| Risk Assessment | 7 | 2019 | 225 | 0.480 |
Why?
|
| Endemic Diseases | 1 | 2016 | 15 | 0.480 |
Why?
|
| Regression Analysis | 10 | 2019 | 133 | 0.480 |
Why?
|
| Motivational Interviewing | 1 | 2016 | 10 | 0.480 |
Why?
|
| Genomics | 5 | 2021 | 109 | 0.470 |
Why?
|
| Atherosclerosis | 3 | 2022 | 100 | 0.470 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 24 | 0.470 |
Why?
|
| Abdominal Fat | 1 | 2015 | 6 | 0.460 |
Why?
|
| Biomedical Research | 1 | 2016 | 49 | 0.460 |
Why?
|
| Population Dynamics | 3 | 2012 | 27 | 0.460 |
Why?
|
| Child Behavior Disorders | 3 | 2010 | 7 | 0.460 |
Why?
|
| Menopause | 5 | 2023 | 24 | 0.460 |
Why?
|
| Brazil | 11 | 2024 | 47 | 0.450 |
Why?
|
| Fetal Macrosomia | 3 | 2020 | 4 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 244 | 0.450 |
Why?
|
| Lumbar Vertebrae | 7 | 2023 | 18 | 0.450 |
Why?
|
| Maternal Age | 6 | 2020 | 22 | 0.450 |
Why?
|
| War-Related Injuries | 1 | 2015 | 1 | 0.440 |
Why?
|
| Social Problems | 1 | 2015 | 1 | 0.440 |
Why?
|
| Patient Simulation | 1 | 2015 | 1 | 0.440 |
Why?
|
| Kenya | 9 | 2023 | 183 | 0.440 |
Why?
|
| Nurses | 2 | 2014 | 32 | 0.440 |
Why?
|
| Counseling | 4 | 2017 | 143 | 0.440 |
Why?
|
| Rural Health Services | 2 | 2014 | 48 | 0.430 |
Why?
|
| Carotid Intima-Media Thickness | 5 | 2022 | 108 | 0.430 |
Why?
|
| Metacarpal Bones | 4 | 2018 | 9 | 0.430 |
Why?
|
| Delphi Technique | 4 | 2021 | 30 | 0.430 |
Why?
|
| Perception | 3 | 2020 | 42 | 0.430 |
Why?
|
| Malaysia | 5 | 2022 | 7 | 0.430 |
Why?
|
| Vaccination | 3 | 2025 | 365 | 0.420 |
Why?
|
| Incidence | 12 | 2025 | 685 | 0.420 |
Why?
|
| Contraception | 1 | 2015 | 90 | 0.420 |
Why?
|
| Executive Function | 3 | 2019 | 23 | 0.410 |
Why?
|
| Judgment | 1 | 2014 | 2 | 0.410 |
Why?
|
| Predictive Value of Tests | 4 | 2022 | 188 | 0.410 |
Why?
|
| Family Practice | 1 | 2013 | 7 | 0.410 |
Why?
|
| Phenotype | 6 | 2025 | 158 | 0.410 |
Why?
|
| Specialization | 1 | 2013 | 8 | 0.410 |
Why?
|
| Vitamin D Deficiency | 4 | 2021 | 27 | 0.400 |
Why?
|
| Polymorphism, Genetic | 4 | 2018 | 99 | 0.400 |
Why?
|
| Communicable Diseases | 3 | 2018 | 62 | 0.400 |
Why?
|
| HIV-1 | 5 | 2020 | 1260 | 0.400 |
Why?
|
| Cognition | 4 | 2023 | 75 | 0.400 |
Why?
|
| Cholangitis, Sclerosing | 3 | 2001 | 3 | 0.390 |
Why?
|
| Hepacivirus | 4 | 2017 | 37 | 0.390 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2002 | 51 | 0.380 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 468 | 0.380 |
Why?
|
| Liver Neoplasms | 3 | 2002 | 59 | 0.380 |
Why?
|
| Anti-HIV Agents | 8 | 2020 | 1324 | 0.380 |
Why?
|
| Health Personnel | 6 | 2021 | 231 | 0.370 |
Why?
|
| Plethysmography | 3 | 2024 | 5 | 0.370 |
Why?
|
| Case-Control Studies | 9 | 2022 | 480 | 0.370 |
Why?
|
| Severe Acute Malnutrition | 2 | 2022 | 2 | 0.370 |
Why?
|
| Hygiene | 4 | 2020 | 23 | 0.370 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 101 | 0.370 |
Why?
|
| Environment | 5 | 2018 | 22 | 0.370 |
Why?
|
| Parathyroid Hormone | 4 | 2015 | 13 | 0.360 |
Why?
|
| Linear Models | 5 | 2019 | 83 | 0.360 |
Why?
|
| Social Behavior | 1 | 2011 | 5 | 0.360 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 5 | 0.360 |
Why?
|
| Risk | 5 | 2015 | 87 | 0.350 |
Why?
|
| Child Nutrition Disorders | 4 | 2015 | 13 | 0.350 |
Why?
|
| Poverty Areas | 3 | 2017 | 20 | 0.350 |
Why?
|
| Cell Phone | 3 | 2021 | 34 | 0.340 |
Why?
|
| Sex Distribution | 5 | 2018 | 89 | 0.340 |
Why?
|
| Microbiota | 2 | 2022 | 30 | 0.340 |
Why?
|
| Research Report | 3 | 2022 | 11 | 0.340 |
Why?
|
| Calcium, Dietary | 3 | 2014 | 25 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2024 | 27 | 0.330 |
Why?
|
| India | 8 | 2024 | 62 | 0.320 |
Why?
|
| Infant, Low Birth Weight | 2 | 2017 | 35 | 0.320 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 385 | 0.320 |
Why?
|
| Infant, Premature | 2 | 2021 | 56 | 0.320 |
Why?
|
| Water Supply | 2 | 2020 | 10 | 0.320 |
Why?
|
| Postpartum Period | 3 | 2023 | 85 | 0.320 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 7 | 0.310 |
Why?
|
| Child Abuse | 2 | 2022 | 10 | 0.310 |
Why?
|
| Demography | 5 | 2021 | 105 | 0.310 |
Why?
|
| Consensus | 3 | 2021 | 62 | 0.310 |
Why?
|
| Gene Frequency | 7 | 2024 | 122 | 0.300 |
Why?
|
| Genetics, Population | 3 | 2021 | 52 | 0.300 |
Why?
|
| Delayed Diagnosis | 2 | 2020 | 17 | 0.300 |
Why?
|
| Lymphocytes | 2 | 2020 | 20 | 0.300 |
Why?
|
| Culture | 3 | 2024 | 23 | 0.300 |
Why?
|
| Liver Transplantation | 5 | 2015 | 55 | 0.300 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2021 | 187 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 127 | 0.290 |
Why?
|
| Motor Skills | 2 | 2019 | 6 | 0.290 |
Why?
|
| Body Weights and Measures | 2 | 2019 | 17 | 0.290 |
Why?
|
| Liver Cirrhosis | 3 | 2017 | 28 | 0.290 |
Why?
|
| Immune Tolerance | 2 | 2016 | 22 | 0.290 |
Why?
|
| Tibia | 3 | 2022 | 14 | 0.290 |
Why?
|
| Research Subjects | 1 | 2008 | 4 | 0.290 |
Why?
|
| Placenta | 4 | 2023 | 44 | 0.290 |
Why?
|
| Patient Participation | 1 | 2008 | 13 | 0.290 |
Why?
|
| Primary Health Care | 2 | 2021 | 240 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 176 | 0.280 |
Why?
|
| Databases, Factual | 2 | 2019 | 64 | 0.270 |
Why?
|
| Reproductive Health | 2 | 2020 | 51 | 0.270 |
Why?
|
| Self Disclosure | 1 | 2007 | 8 | 0.270 |
Why?
|
| Mass Screening | 2 | 2021 | 245 | 0.270 |
Why?
|
| Genome, Human | 2 | 2020 | 25 | 0.270 |
Why?
|
| Risk Reduction Behavior | 3 | 2016 | 39 | 0.270 |
Why?
|
| Healthy Lifestyle | 2 | 2019 | 9 | 0.270 |
Why?
|
| Pregnant Women | 5 | 2024 | 89 | 0.270 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 10 | 0.270 |
Why?
|
| Disease Progression | 7 | 2019 | 154 | 0.260 |
Why?
|
| Ghana | 6 | 2025 | 67 | 0.260 |
Why?
|
| Social Norms | 2 | 2019 | 8 | 0.260 |
Why?
|
| Ferritins | 2 | 2023 | 23 | 0.260 |
Why?
|
| Treatment Outcome | 8 | 2020 | 889 | 0.260 |
Why?
|
| Factor V | 1 | 2007 | 10 | 0.260 |
Why?
|
| Prothrombin | 1 | 2007 | 8 | 0.260 |
Why?
|
| Emotions | 2 | 2024 | 18 | 0.250 |
Why?
|
| Cross-Cultural Comparison | 2 | 2019 | 16 | 0.250 |
Why?
|
| Animals | 9 | 2023 | 1081 | 0.250 |
Why?
|
| Thrombosis | 1 | 2007 | 47 | 0.250 |
Why?
|
| Morbidity | 3 | 2021 | 37 | 0.250 |
Why?
|
| Australia | 5 | 2024 | 48 | 0.240 |
Why?
|
| Body Size | 8 | 2021 | 15 | 0.240 |
Why?
|
| Philippines | 6 | 2024 | 10 | 0.240 |
Why?
|
| Pilot Projects | 4 | 2024 | 179 | 0.240 |
Why?
|
| Patient Readmission | 2 | 2022 | 6 | 0.240 |
Why?
|
| Apartheid | 2 | 2023 | 4 | 0.240 |
Why?
|
| Home Care Services | 2 | 2017 | 15 | 0.240 |
Why?
|
| Sexual Partners | 2 | 2018 | 215 | 0.230 |
Why?
|
| Parenting | 2 | 2016 | 22 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2021 | 472 | 0.230 |
Why?
|
| Neoplasm Staging | 3 | 2023 | 50 | 0.230 |
Why?
|
| Lipids | 3 | 2015 | 81 | 0.230 |
Why?
|
| Depressive Disorder | 2 | 2017 | 10 | 0.230 |
Why?
|
| Principal Component Analysis | 3 | 2015 | 20 | 0.230 |
Why?
|
| Genotype | 8 | 2018 | 442 | 0.230 |
Why?
|
| Maternal Exposure | 2 | 2019 | 14 | 0.230 |
Why?
|
| Urban Health Services | 2 | 2016 | 10 | 0.230 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 43 | 0.220 |
Why?
|
| Ribavirin | 3 | 2011 | 15 | 0.220 |
Why?
|
| Metagenome | 1 | 2025 | 6 | 0.220 |
Why?
|
| Child Nutrition Sciences | 1 | 2005 | 1 | 0.220 |
Why?
|
| Community Mental Health Services | 1 | 2024 | 1 | 0.220 |
Why?
|
| Prognosis | 3 | 2022 | 199 | 0.220 |
Why?
|
| Femur Neck | 4 | 2013 | 8 | 0.220 |
Why?
|
| Beverages | 2 | 2020 | 42 | 0.220 |
Why?
|
| Workload | 1 | 2024 | 13 | 0.220 |
Why?
|
| Mental Health Services | 1 | 2024 | 10 | 0.220 |
Why?
|
| Precision Medicine | 1 | 2024 | 10 | 0.220 |
Why?
|
| Factor Analysis, Statistical | 1 | 2024 | 11 | 0.220 |
Why?
|
| Killer Cells, Natural | 2 | 2001 | 52 | 0.220 |
Why?
|
| Sugars | 2 | 2022 | 14 | 0.210 |
Why?
|
| Guatemala | 5 | 2024 | 8 | 0.210 |
Why?
|
| Students | 1 | 2005 | 50 | 0.210 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 9 | 0.210 |
Why?
|
| Geography | 3 | 2021 | 60 | 0.210 |
Why?
|
| Administrative Personnel | 2 | 2023 | 17 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 34 | 0.210 |
Why?
|
| Hot Temperature | 1 | 2024 | 28 | 0.210 |
Why?
|
| Hair | 2 | 2018 | 3 | 0.210 |
Why?
|
| Decision Making | 1 | 2024 | 53 | 0.210 |
Why?
|
| Medical Assistance | 1 | 2023 | 8 | 0.200 |
Why?
|
| Taste Perception | 1 | 2023 | 3 | 0.200 |
Why?
|
| Water | 2 | 2020 | 22 | 0.200 |
Why?
|
| Fathers | 1 | 2023 | 9 | 0.200 |
Why?
|
| Sodium Chloride | 1 | 2023 | 16 | 0.200 |
Why?
|
| Government Programs | 1 | 2024 | 30 | 0.200 |
Why?
|
| Intra-Abdominal Fat | 3 | 2020 | 15 | 0.200 |
Why?
|
| Femur | 2 | 2017 | 11 | 0.200 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2021 | 10 | 0.200 |
Why?
|
| Friends | 2 | 2014 | 6 | 0.200 |
Why?
|
| World Health Organization | 3 | 2014 | 137 | 0.200 |
Why?
|
| Fasting | 2 | 2021 | 16 | 0.200 |
Why?
|
| DNA Methylation | 2 | 2022 | 19 | 0.200 |
Why?
|
| Developed Countries | 3 | 2018 | 24 | 0.200 |
Why?
|
| Odds Ratio | 3 | 2019 | 133 | 0.200 |
Why?
|
| Population Surveillance | 4 | 2018 | 325 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2020 | 2 | 0.200 |
Why?
|
| Quarantine | 1 | 2023 | 5 | 0.200 |
Why?
|
| Confidence Intervals | 2 | 2016 | 26 | 0.200 |
Why?
|
| Feedback | 1 | 2023 | 6 | 0.190 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 12 | 0.190 |
Why?
|
| Canada | 1 | 2023 | 11 | 0.190 |
Why?
|
| Resource Allocation | 1 | 2023 | 16 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2022 | 39 | 0.190 |
Why?
|
| China | 1 | 2023 | 21 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 279 | 0.190 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2023 | 3 | 0.190 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 15 | 0.190 |
Why?
|
| Osteoporosis | 2 | 2017 | 14 | 0.190 |
Why?
|
| Oral Health | 1 | 2023 | 9 | 0.190 |
Why?
|
| Gender Identity | 2 | 2021 | 23 | 0.190 |
Why?
|
| Perinatal Mortality | 2 | 2020 | 11 | 0.190 |
Why?
|
| Radius | 2 | 2022 | 9 | 0.190 |
Why?
|
| Walking | 3 | 2019 | 14 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 65 | 0.190 |
Why?
|
| Quality Improvement | 2 | 2020 | 34 | 0.190 |
Why?
|
| Gene-Environment Interaction | 2 | 2024 | 12 | 0.190 |
Why?
|
| Fungicides, Industrial | 1 | 2022 | 1 | 0.190 |
Why?
|
| Osteoporotic Fractures | 1 | 2022 | 7 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 253 | 0.190 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2022 | 11 | 0.190 |
Why?
|
| Nutrition Surveys | 3 | 2007 | 13 | 0.190 |
Why?
|
| Inflammation | 1 | 2023 | 104 | 0.190 |
Why?
|
| Interferon-alpha | 3 | 2016 | 15 | 0.180 |
Why?
|
| Program Evaluation | 3 | 2021 | 89 | 0.180 |
Why?
|
| Fast Foods | 2 | 2012 | 7 | 0.180 |
Why?
|
| Adenine | 2 | 2020 | 91 | 0.180 |
Why?
|
| Climate Change | 2 | 2024 | 27 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2020 | 85 | 0.180 |
Why?
|
| Anger | 1 | 2022 | 2 | 0.180 |
Why?
|
| Hostility | 1 | 2022 | 3 | 0.180 |
Why?
|
| Ventricular Remodeling | 1 | 2022 | 44 | 0.180 |
Why?
|
| Vascular Stiffness | 1 | 2022 | 41 | 0.180 |
Why?
|
| Public Policy | 2 | 2019 | 24 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 2 | 0.180 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2001 | 3 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2001 | 5 | 0.180 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 56 | 0.180 |
Why?
|
| fas Receptor | 1 | 2001 | 13 | 0.180 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 8 | 0.180 |
Why?
|
| Carotid Artery Diseases | 1 | 2022 | 34 | 0.180 |
Why?
|
| Pregnancy in Adolescence | 2 | 2016 | 15 | 0.180 |
Why?
|
| Cerebral Palsy | 1 | 2021 | 12 | 0.180 |
Why?
|
| Hemophilia A | 2 | 2017 | 106 | 0.170 |
Why?
|
| Text Messaging | 1 | 2021 | 25 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 1999 | 142 | 0.170 |
Why?
|
| Th2 Cells | 1 | 2021 | 2 | 0.170 |
Why?
|
| Vitamins | 1 | 2021 | 23 | 0.170 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 7 | 0.170 |
Why?
|
| Medical History Taking | 1 | 2021 | 6 | 0.170 |
Why?
|
| Th1 Cells | 1 | 2021 | 6 | 0.170 |
Why?
|
| Chemokines | 1 | 2021 | 9 | 0.170 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2021 | 7 | 0.170 |
Why?
|
| Skull | 1 | 2021 | 2 | 0.170 |
Why?
|
| Fetus | 1 | 2021 | 8 | 0.170 |
Why?
|
| Environmental Monitoring | 2 | 2019 | 20 | 0.170 |
Why?
|
| Weight-Bearing | 2 | 2018 | 6 | 0.170 |
Why?
|
| Gene Flow | 1 | 2021 | 9 | 0.170 |
Why?
|
| Calcium | 1 | 2001 | 49 | 0.170 |
Why?
|
| Language | 1 | 2021 | 14 | 0.170 |
Why?
|
| Men | 1 | 2021 | 15 | 0.170 |
Why?
|
| Health Risk Behaviors | 1 | 2021 | 7 | 0.170 |
Why?
|
| Consanguinity | 1 | 2020 | 2 | 0.170 |
Why?
|
| Skeleton | 2 | 2011 | 2 | 0.170 |
Why?
|
| Subcutaneous Fat | 2 | 2020 | 9 | 0.170 |
Why?
|
| Amino Acids, Aromatic | 1 | 2020 | 3 | 0.160 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2020 | 4 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 32 | 0.160 |
Why?
|
| Health Care Costs | 3 | 2016 | 115 | 0.160 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.160 |
Why?
|
| Data Accuracy | 1 | 2020 | 9 | 0.160 |
Why?
|
| Social Perception | 1 | 2020 | 7 | 0.160 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2020 | 1 | 0.160 |
Why?
|
| Flow Cytometry | 3 | 2020 | 67 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 7 | 0.160 |
Why?
|
| Machine Learning | 1 | 2020 | 22 | 0.160 |
Why?
|
| Umbilical Arteries | 1 | 2020 | 2 | 0.160 |
Why?
|
| Colitis | 1 | 2020 | 2 | 0.160 |
Why?
|
| Object Attachment | 1 | 2020 | 3 | 0.160 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 17 | 0.160 |
Why?
|
| Leisure Activities | 3 | 2019 | 9 | 0.160 |
Why?
|
| Congenital Abnormalities | 1 | 2020 | 7 | 0.160 |
Why?
|
| Vascular Resistance | 1 | 2020 | 12 | 0.160 |
Why?
|
| Reference Values | 4 | 2020 | 64 | 0.160 |
Why?
|
| Indium Radioisotopes | 1 | 1999 | 1 | 0.150 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1999 | 1 | 0.150 |
Why?
|
| Schools, Nursery | 1 | 2019 | 2 | 0.150 |
Why?
|
| Child Care | 1 | 2019 | 5 | 0.150 |
Why?
|
| Age of Onset | 2 | 2018 | 32 | 0.150 |
Why?
|
| Coinfection | 3 | 2017 | 276 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 1999 | 6 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2019 | 2 | 0.150 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2019 | 7 | 0.150 |
Why?
|
| Policy | 1 | 2020 | 42 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 10 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2020 | 127 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 61 | 0.150 |
Why?
|
| Polyethylene Glycols | 2 | 2011 | 49 | 0.150 |
Why?
|
| Trace Elements | 1 | 2019 | 3 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 38 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 40 | 0.150 |
Why?
|
| Perinatal Care | 1 | 2019 | 21 | 0.150 |
Why?
|
| Metals, Heavy | 1 | 2019 | 5 | 0.150 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.150 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 28 | 0.150 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 2 | 0.150 |
Why?
|
| Hemochromatosis Protein | 2 | 2010 | 2 | 0.150 |
Why?
|
| Ultrasonography | 5 | 2021 | 77 | 0.150 |
Why?
|
| Infant Care | 1 | 2019 | 10 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2019 | 73 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 74 | 0.140 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2018 | 1 | 0.140 |
Why?
|
| Economic Development | 2 | 2017 | 5 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 20 | 0.140 |
Why?
|
| Travel | 1 | 2018 | 21 | 0.140 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2018 | 1 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2021 | 175 | 0.140 |
Why?
|
| Disclosure | 1 | 2018 | 25 | 0.140 |
Why?
|
| Publication Bias | 2 | 2016 | 2 | 0.140 |
Why?
|
| Reproductive Health Services | 2 | 2016 | 66 | 0.140 |
Why?
|
| Health Facilities | 1 | 2018 | 40 | 0.140 |
Why?
|
| Graft Survival | 2 | 2016 | 40 | 0.140 |
Why?
|
| Radioactive Waste | 1 | 2017 | 1 | 0.140 |
Why?
|
| Nutritional Sciences | 1 | 2017 | 1 | 0.140 |
Why?
|
| Genetics, Medical | 2 | 2014 | 21 | 0.140 |
Why?
|
| Refuse Disposal | 1 | 2017 | 5 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2018 | 43 | 0.130 |
Why?
|
| Anthropology, Physical | 1 | 2017 | 1 | 0.130 |
Why?
|
| Graft Rejection | 2 | 2016 | 15 | 0.130 |
Why?
|
| Pregnancy Trimester, First | 1 | 2017 | 10 | 0.130 |
Why?
|
| Family Relations | 1 | 2017 | 7 | 0.130 |
Why?
|
| Cesarean Section | 1 | 2018 | 87 | 0.130 |
Why?
|
| Liver | 1 | 1998 | 74 | 0.130 |
Why?
|
| Spouse Abuse | 1 | 2017 | 12 | 0.130 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 20 | 0.130 |
Why?
|
| Nutrition Disorders | 1 | 2017 | 3 | 0.130 |
Why?
|
| Mutation | 2 | 2010 | 306 | 0.130 |
Why?
|
| Sex Offenses | 1 | 2017 | 29 | 0.130 |
Why?
|
| Systole | 2 | 2020 | 37 | 0.130 |
Why?
|
| Hemophilia B | 1 | 2017 | 23 | 0.130 |
Why?
|
| Analysis of Variance | 4 | 2013 | 64 | 0.130 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2017 | 6 | 0.130 |
Why?
|
| Head | 1 | 2017 | 8 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2017 | 5 | 0.130 |
Why?
|
| Awareness | 1 | 2017 | 18 | 0.130 |
Why?
|
| Recreation | 1 | 2017 | 4 | 0.130 |
Why?
|
| Conservation of Natural Resources | 1 | 2017 | 5 | 0.130 |
Why?
|
| Sunlight | 2 | 2014 | 3 | 0.130 |
Why?
|
| Education | 1 | 2017 | 22 | 0.130 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2020 | 30 | 0.130 |
Why?
|
| Cholesterol, LDL | 3 | 2025 | 150 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 7 | 0.120 |
Why?
|
| Postnatal Care | 1 | 2016 | 13 | 0.120 |
Why?
|
| Religious Personnel | 1 | 2016 | 1 | 0.120 |
Why?
|
| Value of Life | 1 | 2016 | 2 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 2 | 2021 | 125 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 20 | 0.120 |
Why?
|
| Nutritional Requirements | 1 | 2016 | 6 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2016 | 17 | 0.120 |
Why?
|
| Habits | 1 | 2016 | 1 | 0.120 |
Why?
|
| Spouses | 1 | 2016 | 6 | 0.120 |
Why?
|
| Brain | 1 | 2016 | 53 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 42 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 45 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 26 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 104 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 23 | 0.120 |
Why?
|
| Self Care | 1 | 2015 | 14 | 0.120 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 43 | 0.120 |
Why?
|
| Carbonated Beverages | 1 | 2015 | 9 | 0.120 |
Why?
|
| School Health Services | 1 | 2015 | 19 | 0.120 |
Why?
|
| Maternal Health Services | 1 | 2016 | 52 | 0.120 |
Why?
|
| Health Education | 1 | 2015 | 35 | 0.120 |
Why?
|
| Prehypertension | 1 | 2015 | 2 | 0.110 |
Why?
|
| United States | 3 | 2014 | 132 | 0.110 |
Why?
|
| Burkina Faso | 3 | 2021 | 29 | 0.110 |
Why?
|
| Peer Influence | 1 | 2015 | 4 | 0.110 |
Why?
|
| Child Behavior | 1 | 2015 | 11 | 0.110 |
Why?
|
| Family | 3 | 2020 | 35 | 0.110 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 52 | 0.110 |
Why?
|
| Parent-Child Relations | 1 | 2015 | 16 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2015 | 15 | 0.110 |
Why?
|
| Organ Size | 3 | 2011 | 34 | 0.110 |
Why?
|
| Hand Bones | 1 | 2014 | 1 | 0.110 |
Why?
|
| Wrist | 1 | 2014 | 2 | 0.110 |
Why?
|
| Breast | 2 | 2021 | 10 | 0.110 |
Why?
|
| Ovary | 1 | 2014 | 5 | 0.110 |
Why?
|
| Feeding and Eating Disorders | 1 | 2014 | 4 | 0.110 |
Why?
|
| Television | 2 | 2012 | 7 | 0.110 |
Why?
|
| Politics | 1 | 2015 | 24 | 0.110 |
Why?
|
| Risk-Taking | 3 | 2021 | 121 | 0.110 |
Why?
|
| Reproduction | 1 | 2014 | 25 | 0.110 |
Why?
|
| Diet Surveys | 2 | 2017 | 7 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2014 | 14 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2014 | 23 | 0.110 |
Why?
|
| Health Services | 1 | 2014 | 51 | 0.110 |
Why?
|
| Disease | 1 | 2014 | 12 | 0.110 |
Why?
|
| Physical Fitness | 2 | 2004 | 10 | 0.110 |
Why?
|
| Program Development | 1 | 2014 | 32 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 144 | 0.100 |
Why?
|
| Homozygote | 2 | 2020 | 61 | 0.100 |
Why?
|
| Skin | 1 | 2014 | 38 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 43 | 0.100 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 4 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2014 | 40 | 0.100 |
Why?
|
| Ireland | 3 | 2020 | 3 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 103 | 0.100 |
Why?
|
| RNA, Viral | 4 | 2019 | 303 | 0.100 |
Why?
|
| Waist-Hip Ratio | 2 | 2025 | 29 | 0.100 |
Why?
|
| Professional Competence | 1 | 2013 | 5 | 0.100 |
Why?
|
| Metagenomics | 2 | 2025 | 13 | 0.100 |
Why?
|
| Child Health Services | 1 | 2013 | 35 | 0.100 |
Why?
|
| Body Fluid Compartments | 1 | 2013 | 2 | 0.100 |
Why?
|
| Information Services | 1 | 2013 | 4 | 0.100 |
Why?
|
| Maternal Welfare | 1 | 2013 | 9 | 0.100 |
Why?
|
| Cholesterol | 2 | 2024 | 38 | 0.100 |
Why?
|
| Potassium | 2 | 2023 | 25 | 0.100 |
Why?
|
| Hip | 1 | 2013 | 1 | 0.100 |
Why?
|
| Radiography | 4 | 2018 | 80 | 0.100 |
Why?
|
| Viral Load | 4 | 2020 | 819 | 0.100 |
Why?
|
| Marital Status | 1 | 2013 | 11 | 0.100 |
Why?
|
| Skinfold Thickness | 3 | 2015 | 6 | 0.100 |
Why?
|
| Glucose | 2 | 2022 | 45 | 0.090 |
Why?
|
| Food Preferences | 1 | 2012 | 1 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2012 | 16 | 0.090 |
Why?
|
| Patient Discharge | 2 | 2022 | 27 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2016 | 374 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 253 | 0.090 |
Why?
|
| Alleles | 3 | 2021 | 143 | 0.090 |
Why?
|
| Haplotypes | 3 | 2021 | 125 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 2 | 2002 | 5 | 0.090 |
Why?
|
| Dietary Fats | 2 | 2013 | 7 | 0.090 |
Why?
|
| Mixed Function Oxygenases | 1 | 2011 | 6 | 0.090 |
Why?
|
| Homeostasis | 1 | 2011 | 9 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 9 | 0.090 |
Why?
|
| Patient Dropouts | 2 | 2008 | 18 | 0.090 |
Why?
|
| Tertiary Care Centers | 2 | 2023 | 80 | 0.090 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 64 | 0.090 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 7 | 0.090 |
Why?
|
| Premenopause | 3 | 2019 | 14 | 0.090 |
Why?
|
| Age Determination by Skeleton | 3 | 2011 | 4 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 10 | 0.090 |
Why?
|
| Health Resources | 1 | 2011 | 66 | 0.080 |
Why?
|
| Ceftazidime | 1 | 1991 | 1 | 0.080 |
Why?
|
| Puberty, Precocious | 1 | 2011 | 1 | 0.080 |
Why?
|
| Research | 2 | 2022 | 65 | 0.080 |
Why?
|
| Social Change | 2 | 2009 | 14 | 0.080 |
Why?
|
| Rabbits | 2 | 2001 | 35 | 0.080 |
Why?
|
| Triglycerides | 2 | 2025 | 47 | 0.080 |
Why?
|
| Seasons | 3 | 2019 | 154 | 0.080 |
Why?
|
| Puberty, Delayed | 1 | 2010 | 3 | 0.080 |
Why?
|
| Child of Impaired Parents | 1 | 2010 | 9 | 0.080 |
Why?
|
| Growth Charts | 3 | 2014 | 4 | 0.080 |
Why?
|
| L-Selectin | 1 | 2010 | 7 | 0.080 |
Why?
|
| E-Selectin | 1 | 2010 | 14 | 0.080 |
Why?
|
| P-Selectin | 1 | 2010 | 7 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 20 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 25 | 0.080 |
Why?
|
| Vegetables | 2 | 2020 | 8 | 0.080 |
Why?
|
| Truth Disclosure | 1 | 2009 | 18 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2024 | 40 | 0.080 |
Why?
|
| Piperazines | 2 | 2020 | 82 | 0.080 |
Why?
|
| Oxazines | 2 | 2020 | 81 | 0.080 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2009 | 1 | 0.070 |
Why?
|
| Pyridones | 2 | 2020 | 100 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2019 | 656 | 0.070 |
Why?
|
| Mice | 2 | 2001 | 135 | 0.070 |
Why?
|
| Psoriasis | 1 | 2009 | 10 | 0.070 |
Why?
|
| Waist-Height Ratio | 2 | 2022 | 4 | 0.070 |
Why?
|
| Birth Certificates | 1 | 2008 | 4 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2009 | 17 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 1 | 0.070 |
Why?
|
| Reference Standards | 1 | 2009 | 29 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 3 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2020 | 8 | 0.070 |
Why?
|
| Software | 2 | 2017 | 37 | 0.070 |
Why?
|
| Internationality | 2 | 2020 | 36 | 0.070 |
Why?
|
| Estradiol | 2 | 2014 | 18 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2008 | 2 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2008 | 6 | 0.070 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Weaning | 1 | 2008 | 4 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 20 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 418 | 0.070 |
Why?
|
| Birth Rate | 2 | 2006 | 5 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 51 | 0.070 |
Why?
|
| Voice | 1 | 2007 | 1 | 0.070 |
Why?
|
| Group Processes | 1 | 2007 | 3 | 0.070 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 4 | 0.070 |
Why?
|
| Genitalia, Male | 1 | 2007 | 9 | 0.070 |
Why?
|
| Transferrin | 1 | 2007 | 5 | 0.070 |
Why?
|
| Heterozygote | 1 | 2007 | 43 | 0.070 |
Why?
|
| Dietary Fiber | 1 | 2007 | 1 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 4 | 0.060 |
Why?
|
| Dietary Proteins | 1 | 2007 | 4 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2020 | 120 | 0.060 |
Why?
|
| Data Collection | 2 | 2022 | 86 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2006 | 15 | 0.060 |
Why?
|
| International Cooperation | 2 | 2020 | 50 | 0.060 |
Why?
|
| Size Perception | 1 | 2006 | 1 | 0.060 |
Why?
|
| Metacarpus | 1 | 2006 | 2 | 0.060 |
Why?
|
| Food | 1 | 2006 | 11 | 0.060 |
Why?
|
| Calcaneus | 1 | 2006 | 14 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2003 | 150 | 0.060 |
Why?
|
| Atlases as Topic | 1 | 2025 | 5 | 0.060 |
Why?
|
| Treponema | 1 | 2025 | 5 | 0.060 |
Why?
|
| 25-Hydroxyvitamin D 2 | 2 | 2015 | 4 | 0.060 |
Why?
|
| Calcifediol | 2 | 2015 | 6 | 0.060 |
Why?
|
| Deuterium | 1 | 2024 | 1 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 73 | 0.050 |
Why?
|
| Sri Lanka | 1 | 2024 | 4 | 0.050 |
Why?
|
| Curriculum | 1 | 2005 | 27 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 48 | 0.050 |
Why?
|
| Asia | 2 | 2014 | 72 | 0.050 |
Why?
|
| Dietary Sucrose | 2 | 2015 | 17 | 0.050 |
Why?
|
| Mathematics | 1 | 2004 | 3 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2024 | 4 | 0.050 |
Why?
|
| Gravidity | 1 | 2024 | 2 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 10 | 0.050 |
Why?
|
| Taste | 1 | 2023 | 3 | 0.050 |
Why?
|
| Potassium Chloride | 1 | 2023 | 4 | 0.050 |
Why?
|
| Affect | 1 | 2023 | 4 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 62 | 0.050 |
Why?
|
| Sodium | 1 | 2023 | 30 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 23 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 38 | 0.050 |
Why?
|
| Uganda | 1 | 2023 | 197 | 0.050 |
Why?
|
| Age Distribution | 2 | 2017 | 107 | 0.050 |
Why?
|
| CD4 Antigens | 1 | 2003 | 49 | 0.050 |
Why?
|
| State Government | 1 | 2023 | 1 | 0.050 |
Why?
|
| New South Wales | 1 | 2023 | 4 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 34 | 0.050 |
Why?
|
| Minisatellite Repeats | 1 | 2022 | 3 | 0.050 |
Why?
|
| Mental Recall | 2 | 2017 | 3 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 13 | 0.050 |
Why?
|
| C-Peptide | 1 | 2022 | 13 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Oxylipins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Placentation | 1 | 2022 | 2 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 11 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Zambia | 1 | 2022 | 115 | 0.050 |
Why?
|
| ROC Curve | 1 | 2022 | 51 | 0.050 |
Why?
|
| Zimbabwe | 1 | 2022 | 120 | 0.050 |
Why?
|
| Brachial Artery | 1 | 2022 | 29 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 260 | 0.050 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2002 | 1 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Albuminuria | 1 | 2022 | 20 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Activins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2022 | 61 | 0.050 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2001 | 1 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2001 | 5 | 0.040 |
Why?
|
| CD3 Complex | 1 | 2001 | 14 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2022 | 65 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2021 | 24 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 38 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2001 | 23 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 7 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2001 | 3 | 0.040 |
Why?
|
| Intelligence | 1 | 2021 | 6 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 48 | 0.040 |
Why?
|
| Models, Animal | 1 | 2001 | 3 | 0.040 |
Why?
|
| Pregnancy Trimesters | 1 | 2021 | 3 | 0.040 |
Why?
|
| Bone Remodeling | 1 | 2001 | 11 | 0.040 |
Why?
|
| Self-Injurious Behavior | 1 | 2021 | 4 | 0.040 |
Why?
|
| Calcitriol | 1 | 2001 | 6 | 0.040 |
Why?
|
| Amino Acids | 1 | 2001 | 16 | 0.040 |
Why?
|
| Democratic Republic of the Congo | 1 | 2021 | 10 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2001 | 46 | 0.040 |
Why?
|
| Linguistics | 1 | 2021 | 5 | 0.040 |
Why?
|
| Isoantigens | 1 | 2001 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Y | 1 | 2021 | 9 | 0.040 |
Why?
|
| Cephalometry | 1 | 2021 | 2 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 20 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 7 | 0.040 |
Why?
|
| Reproductive History | 1 | 2021 | 2 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 17 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2002 | 125 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2021 | 8 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 17 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 14 | 0.040 |
Why?
|
| South America | 1 | 2020 | 27 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 14 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 17 | 0.040 |
Why?
|
| Rats | 1 | 2001 | 130 | 0.040 |
Why?
|
| Inbreeding Depression | 1 | 2020 | 1 | 0.040 |
Why?
|
| Genes, Recessive | 1 | 2020 | 5 | 0.040 |
Why?
|
| Urbanization | 1 | 2020 | 11 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 11 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 18 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 30 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 151 | 0.040 |
Why?
|
| Epitopes | 1 | 2001 | 97 | 0.040 |
Why?
|
| Infant, Extremely Premature | 1 | 2020 | 1 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 31 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2020 | 10 | 0.040 |
Why?
|
| Receptors, CCR6 | 1 | 2020 | 1 | 0.040 |
Why?
|
| Biometry | 1 | 2020 | 5 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 149 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2000 | 9 | 0.040 |
Why?
|
| Bacteria | 1 | 2020 | 47 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2000 | 12 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 231 | 0.040 |
Why?
|
| Emtricitabine | 1 | 2020 | 78 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 1 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2020 | 1 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 151 | 0.040 |
Why?
|
| Alkynes | 1 | 2020 | 117 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2020 | 123 | 0.040 |
Why?
|
| Accelerometry | 1 | 2020 | 19 | 0.040 |
Why?
|
| Quality of Life | 1 | 2021 | 177 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pregnancy, Multiple | 1 | 2020 | 4 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2000 | 1 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2020 | 4 | 0.040 |
Why?
|
| Benzoxazines | 1 | 2020 | 123 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 33 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 1 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 4 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 43 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 17 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 105 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 106 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 11 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2019 | 2 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 30 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Public Sector | 1 | 2020 | 82 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 17 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 41 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 10 | 0.040 |
Why?
|
| Goals | 1 | 2019 | 7 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2019 | 8 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Tenofovir | 1 | 2020 | 171 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 32 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 38 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 55 | 0.040 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 7 | 0.040 |
Why?
|
| Meat | 1 | 2019 | 3 | 0.040 |
Why?
|
| Fruit | 1 | 2019 | 5 | 0.040 |
Why?
|
| Exercise Test | 1 | 2018 | 13 | 0.040 |
Why?
|
| Housing | 2 | 2010 | 24 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2018 | 16 | 0.040 |
Why?
|
| Sports | 1 | 2019 | 43 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2018 | 5 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 10 | 0.030 |
Why?
|
| Financial Support | 1 | 2018 | 10 | 0.030 |
Why?
|
| Radiation Monitoring | 1 | 2017 | 1 | 0.030 |
Why?
|
| Radioactivity | 1 | 2017 | 1 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 6 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1998 | 24 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 65 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1998 | 26 | 0.030 |
Why?
|
| Diet Records | 1 | 2017 | 1 | 0.030 |
Why?
|
| Pyridines | 1 | 1997 | 11 | 0.030 |
Why?
|
| Phosphates | 1 | 2017 | 10 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 106 | 0.030 |
Why?
|
| Fetal Weight | 1 | 2017 | 5 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 19 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 163 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 25 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 91 | 0.030 |
Why?
|
| Neurosciences | 1 | 2016 | 2 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2016 | 3 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 12 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1997 | 118 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 34 | 0.030 |
Why?
|
| Leadership | 1 | 2016 | 23 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 91 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 27 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2015 | 3 | 0.030 |
Why?
|
| Heterosexuality | 1 | 2016 | 30 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 18 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 54 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 26 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2015 | 6 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 10 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2014 | 11 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 31 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 56 | 0.030 |
Why?
|
| Economics | 1 | 2014 | 5 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 20 | 0.030 |
Why?
|
| Health Transition | 1 | 2014 | 11 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 11 | 0.030 |
Why?
|
| England | 1 | 2014 | 15 | 0.030 |
Why?
|
| Health | 1 | 2014 | 11 | 0.030 |
Why?
|
| Bottle Feeding | 1 | 2013 | 4 | 0.030 |
Why?
|
| Chest Pain | 1 | 1993 | 3 | 0.030 |
Why?
|
| Minority Groups | 1 | 1993 | 4 | 0.030 |
Why?
|
| Diaphyses | 1 | 2013 | 2 | 0.030 |
Why?
|
| Muscles | 1 | 2013 | 3 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 9 | 0.030 |
Why?
|
| Patient Admission | 1 | 1993 | 11 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 38 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 6 | 0.020 |
Why?
|
| Hip Joint | 1 | 2013 | 3 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2013 | 97 | 0.020 |
Why?
|
| Confidentiality | 1 | 2012 | 13 | 0.020 |
Why?
|
| Food Services | 1 | 2012 | 1 | 0.020 |
Why?
|
| Commerce | 1 | 2012 | 22 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Population | 1 | 2011 | 5 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2011 | 11 | 0.020 |
Why?
|
| Nigeria | 1 | 2011 | 49 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2011 | 11 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2011 | 57 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 37 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1991 | 11 | 0.020 |
Why?
|
| Half-Life | 1 | 1991 | 22 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 14 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1991 | 156 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 3 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2010 | 27 | 0.020 |
Why?
|
| Prejudice | 1 | 2009 | 8 | 0.020 |
Why?
|
| Child Welfare | 1 | 2009 | 16 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 2 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 2 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 10 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 17 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 62 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 2008 | 4 | 0.020 |
Why?
|
| Infant Food | 1 | 2008 | 4 | 0.020 |
Why?
|
| Minnesota | 1 | 2007 | 2 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2007 | 3 | 0.020 |
Why?
|
| Hand Strength | 1 | 2007 | 7 | 0.020 |
Why?
|
| Patient Selection | 1 | 2007 | 40 | 0.020 |
Why?
|
| Fibrosis | 1 | 2006 | 11 | 0.020 |
Why?
|
| Weights and Measures | 1 | 2006 | 1 | 0.010 |
Why?
|
| Photography | 1 | 2006 | 5 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 20 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 41 | 0.010 |
Why?
|
| London | 1 | 2002 | 8 | 0.010 |
Why?
|
| Prednisolone | 1 | 2002 | 10 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2002 | 26 | 0.010 |
Why?
|
| Follistatin | 1 | 2002 | 1 | 0.010 |
Why?
|
| Jaundice, Neonatal | 1 | 1982 | 2 | 0.010 |
Why?
|
| Bilirubin | 1 | 1982 | 3 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 40 | 0.010 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2001 | 1 | 0.010 |
Why?
|
| Myeloproliferative Disorders | 1 | 2001 | 1 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 12 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 2 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2000 | 5 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2000 | 5 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 14 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1997 | 7 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1997 | 9 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 1997 | 14 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 1997 | 7 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 60 | 0.010 |
Why?
|
| Nevirapine | 1 | 1997 | 146 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 165 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 1997 | 247 | 0.010 |
Why?
|
| Los Angeles | 1 | 1993 | 1 | 0.010 |
Why?
|
| African Americans | 1 | 1993 | 47 | 0.010 |
Why?
|
| Phototherapy | 1 | 1982 | 6 | 0.000 |
Why?
|